CONTEXT: GH and IGF-I have important roles in the maintenance of substrate metabolism and body composition. However, when in excess in acromegaly, the lipolytic and insulin antagonistic effects of GH may alter adipose tissue (AT) deposition. OBJECTIVES: The purpose of this study was to examine the effect of surgery for acromegaly on AT distribution and ectopic lipid deposition in liver and muscle. DESIGN: This was a prospective study before and up to 2 years after pituitary surgery. SETTING: The setting was an academic pituitary center. PATIENTS: Participants were 23 patients with newly diagnosed, untreated acromegaly. MAIN OUTCOME MEASURES: We determined visceral (VAT), subcutaneous (SAT), and intermuscular adipose tissue (IMAT), and skeletal muscle compartments by total-body magnetic resonance imaging, intrahepatic and intramyocellular lipid by proton magnetic resonance spectroscopy, and serum endocrine, metabolic, and cardiovascular risk markers. RESULTS: VAT and SAT masses were lower than predicted in active acromegaly, but increased after surgery in male and female subjects along with lowering of GH, IGF-I, and insulin resistance. VAT and SAT increased to a greater extent in men than in women. Skeletal muscle mass decreased in men. IMAT was higher in active acromegaly and decreased in women after surgery. Intrahepatic lipid increased, but intramyocellular lipid did not change after surgery. CONCLUSIONS: Acromegaly may present a unique type of lipodystrophy characterized by reduced storage of AT in central depots and a shift of excess lipid to IMAT. After surgery, this pattern partially reverses, but differentially in men and women. These findings have implications for understanding the role of GH in body composition and metabolic risk in acromegaly and other clinical settings of GH use.
CONTEXT: GH and IGF-I have important roles in the maintenance of substrate metabolism and body composition. However, when in excess in acromegaly, the lipolytic and insulin antagonistic effects of GH may alter adipose tissue (AT) deposition. OBJECTIVES: The purpose of this study was to examine the effect of surgery for acromegaly on AT distribution and ectopic lipid deposition in liver and muscle. DESIGN: This was a prospective study before and up to 2 years after pituitary surgery. SETTING: The setting was an academic pituitary center. PATIENTS: Participants were 23 patients with newly diagnosed, untreated acromegaly. MAIN OUTCOME MEASURES: We determined visceral (VAT), subcutaneous (SAT), and intermuscular adipose tissue (IMAT), and skeletal muscle compartments by total-body magnetic resonance imaging, intrahepatic and intramyocellular lipid by proton magnetic resonance spectroscopy, and serum endocrine, metabolic, and cardiovascular risk markers. RESULTS: VAT and SAT masses were lower than predicted in active acromegaly, but increased after surgery in male and female subjects along with lowering of GH, IGF-I, and insulin resistance. VAT and SAT increased to a greater extent in men than in women. Skeletal muscle mass decreased in men. IMAT was higher in active acromegaly and decreased in women after surgery. Intrahepaticlipid increased, but intramyocellular lipid did not change after surgery. CONCLUSIONS:Acromegaly may present a unique type of lipodystrophy characterized by reduced storage of AT in central depots and a shift of excess lipid to IMAT. After surgery, this pattern partially reverses, but differentially in men and women. These findings have implications for understanding the role of GH in body composition and metabolic risk in acromegaly and other clinical settings of GH use.
Authors: Carlos Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Celina Crisman; Irene M Conwell; Jane Kostadinov; Eliza B Geer; Kalmon D Post; Pamela U Freda Journal: J Clin Endocrinol Metab Date: 2014-08-19 Impact factor: 5.958
Authors: Yvonne Winhofer; Peter Wolf; Martin Krššák; Stefan Wolfsberger; Andrea Tura; Giovanni Pacini; Alois Gessl; Wolfgang Raber; Ivica Just Kukurova; Alexandra Kautzky-Willer; Engelbert Knosp; Siegfried Trattnig; Michael Krebs; Anton Luger Journal: J Clin Endocrinol Metab Date: 2014-08-22 Impact factor: 5.958
Authors: Polyxeni Koutkia; Bridget Canavan; Jeff Breu; Martin Torriani; John Kissko; Steven Grinspoon Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Jeremy W Tomlinson; Nicola Crabtree; Penny M S Clark; Geoff Holder; Andrew A Toogood; Cedric H L Shackleton; Paul M Stewart Journal: J Clin Endocrinol Metab Date: 2003-05 Impact factor: 5.958
Authors: Miriam A Bredella; Melanie Schorr; Laura E Dichtel; Anu V Gerweck; Brian J Young; Whitney W Woodmansee; Brooke Swearingen; Karen K Miller Journal: J Clin Endocrinol Metab Date: 2017-11-01 Impact factor: 5.958
Authors: Paul Fellinger; Peter Wolf; Lorenz Pfleger; Patrik Krumpolec; Martin Krssak; Kristaps Klavins; Stefan Wolfsberger; Alexander Micko; Patricia Carey; Bettina Gürtl; Greisa Vila; Wolfgang Raber; Clemens Fürnsinn; Thomas Scherer; Siegfried Trattnig; Alexandra Kautzky-Willer; Michael Krebs; Yvonne Winhofer Journal: JCI Insight Date: 2020-03-12
Authors: Edward O List; Darlene E Berryman; Mathew Buchman; Caitlin Parker; Kevin Funk; Stephen Bell; Silvana Duran-Ortiz; Yanrong Qian; Jonathan A Young; Cody Wilson; Julie Slyby; Savannah McKenna; Elizabeth A Jensen; John J Kopchick Journal: Endocrinology Date: 2019-01-01 Impact factor: 4.736
Authors: Silvana Duran-Ortiz; Jonathan A Young; Adam Jara; Elizabeth A Jensen; Reetobrata Basu; Edward O List; Yanrong Qian; John J Kopchick; Darlene E Berryman Journal: J Neuroendocrinol Date: 2020-10-12 Impact factor: 3.627